title: Effects of the combination of lipopolysaccharide-specific monoclonal antibodies and sparfloxacin against Pseudomonas aeruginosa pneumonia in neutropenic mice.
abstract: The effects of the combination of a murine monoclonal antibody (MAb) specific for the O side chain of Pseudomonas aeruginosa Fisher immunotype 1 lipopolysaccharide and sparfloxacin in a neutropenic mouse model of P. aeruginosa pneumonia were examined. Under the condition that neither MAb at a dose of 500 micrograms per mouse administered intravenously nor a suboptimal dose of oral sparfloxacin (5 mg/kg of body weight) protected mice from challenge with a fatal dose, the combination therapy with MAb and sparfloxacin caused a significant increase in the survival rate (P less than 0.001 compared with either treatment alone). The effect of the combination was closely correlated to bacterial killing in plasma and lung tissue of infected mice. In vitro, a significant MAb-dependent, complement-mediated killing of P. aeruginosa was documented in the presence of sparfloxacin at one-half the MIC, while the killing was not observed in the absence of sparfloxacin. These in vivo and in vitro data suggest the usefulness of combination therapy with a lipopolysaccharide-reactive immunoglobulin G MAb and sparfloxacin in neutropenic patients with P. aeruginosa pneumonia.
authors.affiliation: Department of Internal Medicine, Nagasaki University, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Oishi
authors.forename: F
authors.initials: F
authors.lastname: Sonoda
authors.forename: A
authors.initials: A
authors.lastname: Iwagaki
authors.forename: S
authors.initials: S
authors.lastname: Kobayashi
authors.forename: T
authors.initials: T
authors.lastname: Nagatake
authors.forename: K
authors.initials: K
authors.lastname: Matsumoto
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000633:toxicity; D004359:Drug Therapy, Combination; D005260:Female; D024841:Fluoroquinolones; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007275:Injections, Intravenous; D008070:Lipopolysaccharides / Q000276:immunology; D008168:Lung / Q000187:drug effects; D051379:Mice; D008813:Mice, Inbred ICR; D009503:Neutropenia / Q000139:chemically induced / Q000188:drug therapy*; D011014:Pneumonia / Q000188:drug therapy / Q000382:microbiology; D011552:Pseudomonas Infections / Q000188:drug therapy*; D015363:Quinolones / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*
chemical_list: D000890:Anti-Infective Agents; D000911:Antibodies, Monoclonal; D024841:Fluoroquinolones; D007074:Immunoglobulin G; D008070:Lipopolysaccharides; D015363:Quinolones; D003520:Cyclophosphamide; C061363:sparfloxacin